Skip to main content
. 2017 Nov 3;4(4):ofx239. doi: 10.1093/ofid/ofx239

Table 1.

BMI Changes in 1118 Patients on Dolutegravir, Raltegravir, Elvitegravir, Darunavir, or Rilpivirine, Before and After Adjustment for Baseline Characteristics, and After Stratification for CDC Stage of Disease, CD4+ at Baseline, Previous ART Duration

BMI, mean ± SE, kg/m2 Dolutegravir Raltegravir Elvitegravir Darunavir Rilpivirine
N = 225 N = 382 N = 148 N = 145 N = 218
6-mo visit 0.18 ± 0.08 0.17 ± 0.07 0.21 ± 0.07 0.32 ± 0.09 0.06 ± 0.07
P = .016 P = .014 P = .004 P = .0009 P = .39
12-mo visit 0.30 ± 0.10 0.24 ± 0.08 0.23 ± 0.10 0.41 ± 0.10 0.06 ± 0.08
P = .005 P = .003 P = .017 P = .0001 P = .51
6-mo visita 0.28 ± 0.10 0.26 ± 0.08 0.42 ± 0.11 0.35 ± 0.11 0.30 ± 0.11
P = .006 P = .001 P = .0003 P = .001 P = .005
12-mo visita 0.37 ± 0.13 0.36 ± 0.10 0.42 ± 0.15 0.48 ± 0.14 0.30 ± 0.14
P = .004 P = .0004 P = .004 P = .0006 P = .029
12-mo visit, in strata of:
CDC stage A+Bb 0.22 ± 0.15 0.02 ± 0.12 0.38 ± 0.156 0.36 ± 0.16 0.10 ± 0.15
n = 767 P = .16 P = .90 P = .019 P = .029 P = .51
CDC stage Cb 0.66 ± 0.24 0.86 ± 0.19 0.29 ± 0.30 0.64 ± 0.25 0.63 ± 0.31
n = 351 P = .007 P < .0001 P = .35 P = .012 P = .04
CD4+ ≥200 cells/mLc 0.15 ± 0.14 0.16 ± 0.11 0.33 ± 0.15 0.45 ± 0.16 0.10 ± 0.14
n = 903 P = .28 P = .17 P = .031 P = .005 P = .46
CD4+ <200 cells/mLc 1.24 ± 0.41 0.70 ± 0.25 0.08 ± 0.44 0.46 ± 0.31 1.34 ± 0.66
n = 215 P = .003 P = .006 P = .85 P = .14 P = .044
Previous ART <3 yd 0.68 ± 0.42 0.78 ± 0.35 0.32 ± 0.42 1.42 ± 0.51 0.08 ± 0.40
n = 195 P = .11 P = .029 P = .45 P = .006 P = .85
Previous ART ≥3 yd 0.34 ± 0.13 0.32 ± 0.09 0.50 ± 0.16 0.38 ± 0.13 0.36 ± 0.14
n = 921 P = .009 P = .0007 P = .001 P = .004 P = .011

P refers to change from baseline: if P < .05, means are significantly different from 0.

aAdjusted for sex, age, CD4+, detectable viral load, CDC stage, duration of ART, lipodystrophy, and BMI at study entry.

bAdjusted for sex, age, CD4+, detectable viral load, duration of ART, lipodystrophy, and BMI at study entry.

cAdjusted for sex, age, detectable viral load, CDC stage, duration of ART, lipodystrophy, and BMI at study entry.

dAdjusted for sex, age, CD4+, detectable viral load, CDC stage, lipodystrophy, and BMI at study entry.